Purpose Lung adenocarcinoma (LUAD) is the predominant subtype of lung cancer, with
increasing evidence showing clinical benefits of immunotherapy. However, a lack of …

Lung adenocarcinoma is one of the most malignant diseases worldwide. The immune
checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and programmed …

Background Lung cancer has become the most common cancer type and caused the most
cancer deaths. Lung adenocarcinoma (LUAD) is one of the major type of lung cancer. This …

Background Lung adenocarcinomas (LUAD) is the most common histological subtype of
lung cancers. Tumor immune microenvironment (TIME) is involved in tumorigeneses …

Background: Although immunotherapy with checkpoint inhibitors is changing the face of
lung adenocarcinoma (LUAD) treatments, only limited patients could benefit from it …

Background: Immune cells play a critical role in the prognosis of cancer. However, the
function of different immune cell types in lung adenocarcinoma (LUAD) and the …

Background Lung adenocarcinoma (LUAD) is a major subtype of non-small cell lung cancer
(NSCLC) with a highly heterogeneous tumor microenvironment. Immune checkpoint …

Lung adenocarcinoma (LUAD), the most common non‐small‐cell lung cancer, is
characterized by a dense lymphocytic infiltrate, which indicates that the immune system …

Background Lung adenocarcinoma (LUAD) has become the most frequent histologic type of
lung cancer in the past several decades. Recent successes with immune checkpoint …

Background The advent of immunotherapy targeting immune checkpoints has conferred
significant clinical advantages to patients with lung adenocarcinoma (LUAD); However, only …